XGEN.DE vs. ETLI.DE

Last updated Jun 5, 2026

XGEN.DE (Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C) and ETLI.DE (L&G Pharma Breakthrough UCITS ETF) are both Health & Biotech Equities funds - XGEN.DE tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 while ETLI.DE tracks the Solactive Pharma Breakthrough Value. Both are passively managed. Over the past 3 years, XGEN.DE returned 1.39%/yr vs 2.83%/yr for ETLI.DE. A 0.73 correlation means they provide meaningful diversification when combined. XGEN.DE charges 0.30%/yr vs 0.49%/yr for ETLI.DE.

Performance

XGEN.DE vs. ETLI.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, XGEN.DE achieves a -1.40% return, which is significantly lower than ETLI.DE's -0.74% return.

XGEN.DE

• 1D: 3.92%
• 1M: 6.45%
• YTD: -1.40%
• 6M: -3.78%
• 1Y: 22.37%
• 3Y*: 1.39%
• 5Y*: —
• 10Y*: —

ETLI.DE

• 1D: 2.62%
• 1M: -3.54%
• YTD: -0.74%
• 6M: -2.98%
• 1Y: 21.87%
• 3Y*: 2.83%
• 5Y*: 2.31%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

XGEN.DE vs. ETLI.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	-1.40%	7.38%	2.95%	-5.84%	-9.98%
ETLI.DE L&G Pharma Breakthrough UCITS ETF	-0.74%	22.23%	0.42%	-12.64%	-0.93%

Correlation

The correlation between XGEN.DE and ETLI.DE is 0.76, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.76
Correlation (3Y) Calculated over the trailing 3-year period	0.73
Correlation (All Time) Calculated using the full available price history since Jul 20, 2022	0.73

The correlation between XGEN.DE and ETLI.DE has been stable across timeframes, ranging from 0.73 to 0.76 - a consistent structural relationship.

Return for Risk

XGEN.DE vs. ETLI.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XGEN.DE

XGEN.DE Risk / Return Rank: 32
XGEN.DE Sharpe Ratio Rank: 35
XGEN.DE Sortino Ratio Rank: 36
XGEN.DE Omega Ratio Rank: 32
XGEN.DE Calmar Ratio Rank: 30
XGEN.DE Martin Ratio Rank: 26

ETLI.DE

ETLI.DE Risk / Return Rank: 38
ETLI.DE Sharpe Ratio Rank: 33
ETLI.DE Sortino Ratio Rank: 34
ETLI.DE Omega Ratio Rank: 30
ETLI.DE Calmar Ratio Rank: 49
ETLI.DE Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XGEN.DE vs. ETLI.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XGEN.DE	ETLI.DE	Difference
Sharpe ratio: Return per unit of total volatility	1.23	1.16	+0.06
Sortino ratio: Return per unit of downside risk	1.85	1.76	+0.08
Omega ratio: Gain probability vs. loss probability	1.21	1.20	+0.01
Calmar ratio: Return relative to maximum drawdown	1.49	2.40	-0.92
Martin ratio: Return relative to average drawdown	3.61	6.79	-3.18
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XGEN.DE vs. ETLI.DE - Sharpe Ratio Comparison

The current XGEN.DE Sharpe Ratio is 1.23, which is comparable to the ETLI.DE Sharpe Ratio of 1.16. The chart below compares the historical Sharpe Ratios of XGEN.DE and ETLI.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	XGEN.DE	ETLI.DE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.23	1.16	+0.06
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.13	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.11	0.22	-0.33

Drawdowns

XGEN.DE vs. ETLI.DE - Drawdown Comparison

The maximum XGEN.DE drawdown since its inception was -37.58%, which is greater than ETLI.DE's maximum drawdown of -30.83%. Use the drawdown chart below to compare losses from any high point for XGEN.DE and ETLI.DE.

Drawdown Indicators

	XGEN.DE	ETLI.DE	Difference
Max Drawdown Largest peak-to-trough decline	-37.58%	-30.83%	-6.75%
Max Drawdown (1Y) Largest decline over 1 year	-14.99%	-9.06%	-5.93%
Max Drawdown (3Y) Largest decline over 3 years	-28.21%	-24.43%	-3.78%
Max Drawdown (5Y) Largest decline over 5 years	—	-30.83%	—
Current Drawdown Current decline from peak	-14.86%	-4.86%	-10.00%
Average Drawdown Average peak-to-trough decline	-19.44%	-10.22%	-9.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.19%	3.21%	+2.98%

Volatility

XGEN.DE vs. ETLI.DE - Volatility Comparison

The current volatility for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) is 6.48%, while L&G Pharma Breakthrough UCITS ETF (ETLI.DE) has a volatility of 6.89%. This indicates that XGEN.DE experiences smaller price fluctuations and is considered to be less risky than ETLI.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XGEN.DE	ETLI.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.48%	6.89%	-0.41%
Volatility (6M) Calculated over the trailing 6-month period	13.73%	14.09%	-0.36%
Volatility (1Y) Calculated over the trailing 1-year period	18.19%	18.72%	-0.53%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.66%	17.22%	+1.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.66%	18.91%	-0.25%

XGEN.DE vs. ETLI.DE - Expense Ratio Comparison

XGEN.DE has a 0.30% expense ratio, which is lower than ETLI.DE's 0.49% expense ratio.

Dividends

XGEN.DE vs. ETLI.DE - Dividend Comparison

Neither XGEN.DE nor ETLI.DE has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both XGEN.DE and ETLI.DE in my portfolio?

XGEN.DE and ETLI.DE have a correlation of 0.76, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, XGEN.DE or ETLI.DE?

On fees, XGEN.DE is cheaper at 0.30% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, XGEN.DE or ETLI.DE?

XGEN.DE is cheaper with a 0.30% expense ratio, compared with 0.49% for ETLI.DE.

What is the main difference between XGEN.DE and ETLI.DE?

XGEN.DE tracks MSCI ACWI IMI Genomic Innovation Select ESG Screened 100, while ETLI.DE tracks Solactive Pharma Breakthrough Value. They also come from different issuers: Xtrackers and Legal & General. Their fees differ too: 0.30% for XGEN.DE and 0.49% for ETLI.DE.